Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

(2020) José Trigo et al.   LANCET ONCOLOGY

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

(2018) Cristina Cruz et al.   JOURNAL OF CLINICAL ONCOLOGY

Homologous recombination deficiency and ovarian cancer

(2016) Jonathan A. Ledermann et al.   EUROPEAN JOURNAL OF CANCER

Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells

(2016) G. Santamaria Nunez et al.   MOLECULAR CANCER THERAPEUTICS

Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair

(2016) Michelle Lima et al.   Oncotarget

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) J. A. Ledermann et al.   ANNALS OF ONCOLOGY

Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer

(2012) A. Vidal et al.   CLINICAL CANCER RESEARCH

Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer

(2012) Nicoletta Colombo et al.   JOURNAL OF CLINICAL ONCOLOGY

Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells

(2011) D. G. Soares et al.   MOLECULAR CANCER THERAPEUTICS

PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity

(2010) JFM Leal et al.   BRITISH JOURNAL OF PHARMACOLOGY

Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer

(2010) Ignace Vergote et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

(2010) Jalid Sehouli et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

(2009) I. Vergote et al.   EUROPEAN JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER